JP5599788B2 - トリアジンおよびウラシルの誘導体、それらの調製、およびヒト治療薬におけるそれらの応用 - Google Patents

トリアジンおよびウラシルの誘導体、それらの調製、およびヒト治療薬におけるそれらの応用 Download PDF

Info

Publication number
JP5599788B2
JP5599788B2 JP2011517863A JP2011517863A JP5599788B2 JP 5599788 B2 JP5599788 B2 JP 5599788B2 JP 2011517863 A JP2011517863 A JP 2011517863A JP 2011517863 A JP2011517863 A JP 2011517863A JP 5599788 B2 JP5599788 B2 JP 5599788B2
Authority
JP
Japan
Prior art keywords
triazine
dione
trifluoromethyl
methyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011517863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528007A5 (enExample
JP2011528007A (ja
Inventor
イザベル、リロイ
エリザベート、ドュポン‐パセレーグ
カリーヌ、バレイユ
イブ、リバル
ディディエ、ジュンケロ
Original Assignee
ピエール、ファーブル、メディカマン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピエール、ファーブル、メディカマン filed Critical ピエール、ファーブル、メディカマン
Publication of JP2011528007A publication Critical patent/JP2011528007A/ja
Publication of JP2011528007A5 publication Critical patent/JP2011528007A5/ja
Application granted granted Critical
Publication of JP5599788B2 publication Critical patent/JP5599788B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011517863A 2008-07-15 2009-07-07 トリアジンおよびウラシルの誘導体、それらの調製、およびヒト治療薬におけるそれらの応用 Expired - Fee Related JP5599788B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0854794 2008-07-15
FR0854794A FR2933979B1 (fr) 2008-07-15 2008-07-15 Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
PCT/EP2009/058609 WO2010006962A1 (en) 2008-07-15 2009-07-07 Derivatives of triazines and uracils, their preparation and their application in human therapeutics

Publications (3)

Publication Number Publication Date
JP2011528007A JP2011528007A (ja) 2011-11-10
JP2011528007A5 JP2011528007A5 (enExample) 2012-08-30
JP5599788B2 true JP5599788B2 (ja) 2014-10-01

Family

ID=40394394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011517863A Expired - Fee Related JP5599788B2 (ja) 2008-07-15 2009-07-07 トリアジンおよびウラシルの誘導体、それらの調製、およびヒト治療薬におけるそれらの応用

Country Status (7)

Country Link
US (1) US8618287B2 (enExample)
EP (1) EP2328886B1 (enExample)
JP (1) JP5599788B2 (enExample)
AR (1) AR072510A1 (enExample)
FR (1) FR2933979B1 (enExample)
TW (1) TW201006815A (enExample)
WO (1) WO2010006962A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103664873B (zh) 2009-12-30 2016-06-15 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物
FR2958935B1 (fr) 2010-04-19 2012-06-22 Pf Medicament Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine
CN104803971B (zh) * 2014-01-24 2021-11-30 深圳信立泰药业股份有限公司 化合物A单苯甲酸盐的晶型α及其制备方法和含有该晶型的药物组合物
CN105017213B (zh) * 2014-04-30 2017-11-14 成都苑东生物制药股份有限公司 尿嘧啶衍生物
CN107074823B (zh) * 2014-09-05 2021-05-04 基因泰克公司 治疗性化合物及其用途
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
KR20190108118A (ko) 2017-01-06 2019-09-23 유마니티 테라퓨틱스, 인크. 신경계 장애의 치료를 위한 방법
EP3700934A4 (en) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. COMPOUNDS AND USES OF THESE COMPOUNDS
BR112020019191A2 (pt) 2018-03-23 2021-01-05 Yumanity Therapeutics, Inc. Compostos e seus usos
TWI884745B (zh) * 2018-10-12 2025-05-21 美商拓臻股份有限公司 甲狀腺素受體β促效劑化合物
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
EP3914593A4 (en) 2019-01-24 2022-11-02 Yumanity Therapeutics, Inc. CONNECTIONS AND USES THEREOF
EP4028008A4 (en) 2019-09-12 2023-09-13 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
TWI763147B (zh) 2019-11-26 2022-05-01 大陸商昆藥集團股份有限公司 1，2，4-三嗪-3，5-二酮類化合物及其製備方法和應用
WO2024102455A1 (en) * 2022-11-09 2024-05-16 Emory University Non-covalent inhibitors of coronavirus main protease
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5973573A (ja) * 1982-09-09 1984-04-25 ワ−ナ−−ランバ−ト・コンパニ− ジアミノピリミジン化合物
US20050256159A1 (en) * 2002-10-11 2005-11-17 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
AU2006326815A1 (en) * 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase

Also Published As

Publication number Publication date
WO2010006962A1 (en) 2010-01-21
EP2328886B1 (en) 2016-12-28
FR2933979B1 (fr) 2012-08-24
US20110118266A1 (en) 2011-05-19
FR2933979A1 (fr) 2010-01-22
US8618287B2 (en) 2013-12-31
JP2011528007A (ja) 2011-11-10
AR072510A1 (es) 2010-09-01
TW201006815A (en) 2010-02-16
EP2328886A1 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
JP5599788B2 (ja) トリアジンおよびウラシルの誘導体、それらの調製、およびヒト治療薬におけるそれらの応用
US5019575A (en) Novel pyridazinone compounds, compositions thereof and method of use
JP5901520B2 (ja) ２ｈピリダジン−３−オン誘導体、その製造、およびそれらのｓｃｄ−１インヒビターとしての使用
US5824683A (en) 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
US7098210B2 (en) 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
KR20160026997A (ko) 심장 상태에 대한 피리미딘디온 화합물
JPH11158073A (ja) アデノシンａ３拮抗剤
SK4252000A3 (en) Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic
KR101720937B1 (ko) 신규의 트라이아졸론 유도체 또는 그의 염 및 이를 포함하는 약학 조성물
EP1873147A1 (en) Phthalazinone derivative and pharmaceutical comprising the same
SK49499A3 (en) 2-methoxyphenylpiperazine derivatives
EP0597291B1 (en) 2,3-diphenyl-5-pyrrolyl-furan derivatives, processes and intermediates for their preparation and their use as anti-inflammatory, and anti-allergic and platelet aggregation inhibiting agents
US4188388A (en) Phenoxy pyridazinones and anorexigenic use thereof
NO300775B1 (no) Trisykliske triazolderivater samt farmasöytisk middel inneholdende disse
AU2013367084B2 (en) Novel benzazepine derivative and pharmaceutical use thereof
SK51072006A3 (sk) 3-(((4-fenyl)-piperazín-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2H- indol-2-ónové deriváty a s nimi súvisiace zlúčeniny na liečenie ochorení centrálneho nervového systému
JP2815218B2 (ja) ピリミジンジオン誘導体、およびそれを含有する抗不整脈剤
US5185332A (en) Thiadiazines and pharmaceutical compositions thereof as well as method of use
EP1751134A1 (en) Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents
CZ20041085A3 (cs) Nové piperidinyl-alkylamino-pyridazinonové deriváty, způsob jejich přípravy a farmaceutické kompozice je obsahující
HUP0500464A2 (en) Piperazine derivatives of dialkyl-oxindoles
NZ616108A (en) New pyridazinone and pyridone compounds
NZ616108B2 (en) New pyridazinone and pyridone compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120709

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120709

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20131121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140224

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140303

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140422

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140718

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140813

R150 Certificate of patent or registration of utility model

Ref document number: 5599788

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees